Slingshot members are tracking this event:
Interim Phase 1b/2 Results for Merck's (MRK) Keytruda and Eisai's (ESALY) Halaven in Triple-Negative Breast Cancer (TNBC) Presented at the San Antonio Breast Cancer Symposium
Slingshot Insights Explained
Dec 12, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1b/2, Interim Results, Keytruda, Halaven, Metastatic Triple-negative Breast Cancer, Tnbc, San Antonio Breast Cancer Symposium